CCNE2
Cyclin E2: A Key Regulator of Cell Cycle G1/S Transition and Oncogenic Driver
Gene Information Card
| Symbol | CCNE2 |
|---|---|
| Full Name | cyclin E2 |
| Gene Type | protein-coding |
| Chromosomal Location | 8q22.1 |
| NCBI Gene ID | 9134 ncbi.nlm.nih.gov/gene/9134 |
| Ensembl ID | ENSG00000175305 |
| UniProt ID | O96020 |
| OMIM ID | 603847 |
| HGNC ID | 1590 |
| Aliases | CYCE2 |
Description
CCNE2 encodes cyclin E2, a regulatory subunit of cyclin-dependent kinase 2 (CDK2). Cyclin E2 binds CDK2 to drive the G1 to S phase transition of the cell cycle. Overexpression or amplification of CCNE2 is frequently observed in several cancers, including breast and ovarian cancer, and is associated with poor prognosis and resistance to CDK4/6 inhibitors.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | CCNE2 amplification/overexpression leads to CDK2 hyperactivation, promoting unscheduled S-phase entry and genomic instability | PMID: 15361871; COSMIC |
| Ovarian cancer | CCNE2 amplification drives cell cycle progression and contributes to platinum resistance | PMID: 20098429; COSMIC |
| Endometrial cancer | CCNE2 overexpression correlates with aggressive tumor features and poor survival | PMID: 23454725 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.3 | Medium |
| Bone marrow | 8.7 | Medium |
| Lymph node | 6.5 | Low |
| Breast | 4.2 | Low |
| Ovary | 3.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 15.2 | High expression |
| OVCAR3 (ovarian cancer) | 12.8 | High expression |
| HeLa (cervical cancer) | 10.5 | Medium expression |
| A549 (lung cancer) | 7.1 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | missense | <0.1% | Potential loss of start codon; likely loss of function |
| c.832C>T (p.Arg278Trp) | missense | <0.1% | Unknown significance; reported in COSMIC |
| Amplification (8q22.1) | copy number gain | ~10-15% in breast cancer | Increased cyclin E2 expression; oncogenic driver |
Mutation functional classification
Loss of Function (LOF)
Rare missense variants (e.g., p.Met1?) may disrupt protein expression or CDK2 binding, but no established loss-of-function phenotype.
Gain of Function (GOF)
Gene amplification and overexpression are the primary gain-of-function mechanisms, leading to increased CDK2 activity and cell cycle progression.
Dominant Negative (DN)
No dominant-negative mutations have been characterized for CCNE2.
View complete mutation data：
Gene Ontology (GO)
| • cyclin-dependent protein serine/threonine kinase regulator activity | • protein binding |
| • cell cycle | • G1/S transition of mitotic cell cycle |
| • nucleus | • cytoplasm |
Pathways
• Cell Cycle (KEGG hsa04110)
• G1/S Checkpoint (Reactome R-HSA-69278)
• CDK-mediated phosphorylation and removal of Cdc6 (Reactome R-HSA-69017)
Protein Summary
Cyclin E2 is a 404-amino acid protein (molecular weight ~45 kDa) that contains a cyclin N-terminal domain and a cyclin C-terminal domain. It forms a complex with CDK2, and its expression is cell-cycle regulated, peaking at the G1/S boundary. Cyclin E2 is structurally similar to cyclin E1 but encoded by a distinct gene. Its overexpression is oncogenic and linked to chromosomal instability.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CCNE2 Knockout HEK293 Cell Line | EDJ-KQ252 | Human | 9134 | Details Get a Quote |
| CCNE2 Knockout A-549 Cell Line | EDJ-KQ19456 | Human | 9134 | Details Get a Quote |
| CCNE2 Knockout HCT 116 Cell Line | EDJ-KQ19457 | Human | 9134 | Details Get a Quote |
| CCNE2 Knockout HeLa Cell Line | EDJ-KQ19458 | Human | 9134 | Details Get a Quote |
